Barbora Belšánová

Dominance of EGFR and insignificant KRAS mutations in prediction of Tyrosin-kinase therapy for NSCLC patients stratified by tumor subtype and smoking status

2009 | 1. lékařská fakulta, Lékařská fakulta v Plzni

Publikace